Floatz logo

Masitinib

Metastatic Castrate Resistant Prostate Cancer

AB ScienceSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

230 Active assets in the Metastatic Castrate Resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
Bms-907351
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Masitinib is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
61 / 100
View asset →
primary progressive multiple sclerosisDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →